Organisation paid for research Program year 2025 Source: CMS Open Payments

Biopharma Informatic, LLC

Neither a doctor nor a teaching hospital

Research payments

$748,007

695 payments

Through program year 2025, Biopharma Informatic, LLC is reported as receiving $748,007 in research payments, across 695 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$278,145	82
2024	Research	$154,939	29
2023	Research	$62,506	24
2022	Research	$118,792	161
2021	Research	$108,002	391
2020	Research	$7,323	6
2019	Research	$18,300	2

Breakdown

Who paid Research payments · program years 2019–2025

Senseonics, Incorporated $191,125 116 payments
Novo Nordisk AS $176,990 543 payments
Amgen Inc. $166,028 9 payments
Novartis Pharmaceuticals Corporation $154,903 8 payments
Upsher-Smith Laboratories LLC $21,300 4 payments
Hikma Pharmaceuticals USA $18,600 3 payments
Aurinia Pharma U.S., Inc. $8,726 3 payments
Celgene Corporation $8,623 7 payments
E.R. Squibb & Sons, L.L.C. $1,213 1 payment
Merck Sharp & Dohme Corporation $500 1 payment

Studies the money was for Research payments · program years 2019–2025

Nn9931-4553 $151,069 398 payments
Senseonics CTP0039 $130,743 50 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $124,276 2 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $101,537 1 payment
Senseonics CTP-0039 $54,831 64 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $29,882 2 payments
Ex6018-4758 $25,920 145 payments
Ph2b In Subjects with SLE $23,775 2 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy(R) XR in the Prevention of Migraine in Children 6 to 11 Years of Age $21,300 4 payments
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD $15,651 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.